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Abstract
Background: Patient reported outcome measures (PROMs) are widely used in mental healthcare research for quality
of life assessment but most fail to capture the breadth of health and non-health domains that can be impacted. We
report the psychometric validation of a novel, multi-dimensional instrument based on Amartya Sen’s capability
approach intended for use as an outcome measure in mental health research.
Methods: The Oxford Capabilities Questionnaire for Mental Health (OxCAP-MH) is a 16-item self-complete capability
measure that covers multiple domains of functioning and welfare. Data for validation of the instrument were collected
through a national randomised controlled trial of community treatment orders for patients with psychosis. Complete
OxCAP-MH data were available for 172 participants. Internal consistency was established with Cronbach’s alpha; an
interclass correlation coefficient was used to assess test-retest reliability in a sub-sample (N = 50) tested one week apart.
Construct validity was established by comparing OxCAP-MH total scores with established instruments of illness severity
and functioning: EuroQol (EQ-5D), Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning (GAF) and
Objective Social Outcomes Index (SIX). Sensitivity was established by calculating standard error of measurement using
distributional methods.
Results: The OxCAP-MH showed good internal consistency (Cronbach’s alpha 0.79) and test-retest reliability (ICC = 0.86).
Convergent validity was evidenced by strong correlations with the EQ-5D (VAS 0.52, p < .001) (Utility 0.45, p < .001), and
divergent validity through more modest associations with the BPRS (−0.41, p < .001), GAF (0.24, p < .001) and SIX (0.12,
p = ns). A change of 9.2 points on a 0–100 scale was found to be meaningful on statistical grounds.
Conclusions: The OxCAP-MH has demonstrable reliability and construct validity and represents a promising
multi-dimensional alternative to existing patient-reported outcome measures for quality of life used in mental
health research.
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Background
Standardised outcome assessment is widely used in men-
tal health care to evaluate health and social care interven-
tions and to aid decisions about resource allocation. The
use of patient reported outcome measures (PROMs) has
become increasingly popular with the aim of improving
measurement accuracy and increasing patient involve-
ment and satisfaction [1]. The purpose of a PROM is to
assess, from the patient’s perspective, the impact of illness
or an intervention on their life [2]. Studies show that the
systematic use of information generated from PROMs can
improve health outcomes, enhance decision making and
communication between doctors and patients and in-
crease patient satisfaction with care [3–8]. Many estab-
lished PROMs focus on a narrow range of outcomes,
however, and consequently fail to capture the full range of
health and non-health domains that can be impacted by
an illness or intervention [9].
In the United Kingdom and Europe the EQ-5D is one
of the most widely used generic health-related quality of
life PROM [10–12]. The instrument is used in general
and mental health contexts and endorsed by the UK
National Institute for Health and Care Excellence
(NICE) for the calculation of quality adjusted life years
(QALY) used in cost-utility analyses [10, 11, 13]. How-
ever, the EQ-5D has been criticised on methodological
and conceptual grounds. First, it focuses exclusively on
health-related quality of life and consequently fails to
capture non-health benefits and broader welfare inequal-
ities, and, second, it has been shown to lack sensitivity
when applied to mental health populations, particularly
those with psychotic disorders and severe and complex
non-psychotic disorders [9, 14].
Severe mental illnesses are complex health conditions
that lead to poor outcomes in multiple life domains and
there is a need for sophisticated, multi-dimensional
PROMs that are able to capture the breadth of life do-
mains that may be impacted. Amartya Sen’s [15–17]
capability approach, which employs a rich set of dimen-
sions for outcome evaluation, including health and non--
health outcomes, has emerged as an important
alternative conceptual framework for evaluating human
wellbeing [12, 18–21].
According to Sen, well-being should be conceptualised
in terms of a person’s ability to function – that is for the
person to be and do the things that matter to them and
that they have reason to value. These functionings can
range from the rudimentary, such as being adequately
nourished and housed to the more abstract, such as feel-
ing socially valued or achieving self-respect. It is these
‘beings’ and ‘doings’, Sen argues, that make life valuable
to the individual and worth living [16].
Sen distinguishes between functionings – what I do or
am – and capabilities – what I am able or free to do or
be. The distinction between achieved functionings and
capabilities is between that which is realised and that
which is effectively possible [22]. Sen illustrates this dis-
tinction with the example of a person who is starving
and a person who is fasting. In both cases, the functional
outcome is the same – they don’t eat – but their capabil-
ities are different: the first person does not have the cap-
ability to eat while the second person does, but chooses
not to exercise it. What matters for well-being, then, is
not what functionings an individual has achieved, but
rather the genuine opportunities to achieve the function-
ings that matter to that individual.
Health economists and social scientists increasingly
agree that the capability approach offers a richer, more
nuanced theoretical background to the evaluation of
welfare, when compared with the traditional utilitarian
welfarism of QALYs [12, 19, 23].
A small and growing number of capability measures
have been developed for use in a variety of health con-
texts [18]. Within the capability literature the question
of which capabilities are most relevant for individuals or
groups within a given context remains the subject of
much debate. Sen declined to provide an authoritative
list of ‘essential’ capabilities necessary for the good life,
arguing that such a list would necessarily vary, across
time and place, and that individuals and communities
are best placed to decide on such a list. Nussbaum [24]
proposed a list of ten ‘essential’ capabilities including:
‘life’, ‘bodily health’, ‘bodily integrity’, ‘senses, imagination
and thought’, ‘emotions’, ‘practical reason’, ‘affiliation’, ‘other
species’, ‘play’, and ‘control over one’s environment’.
Although Nussbaum’s list is the most widely accepted,
several other lists have emerged, most of which are
highly generic and contain considerable conceptual over-
lap with one another [25].
The OxCAP-MH is the first instrument developed and
operationalised for use as an outcome measure in men-
tal health research [26]. The instrument is designed to
capture the substantive freedoms that an individual has
to be and do the things that they have reason to value
across multiple life domains including: performing usual
activities, meeting socially with friends, not losing sleep
over worry, enjoying recreational activities, having
suitable accommodation, feeling safe, freedom from
discrimination, freedom from assault (including sexual
and domestic), ability to influence local decisions,
freedom to express personal views, appreciation of
nature, respecting and valuing people, enjoying love
friendship and support, self-determination, freedom of
artistic expression and access to interesting activities. A
more thorough discussion of the development of the
instrument as well as the theoretical background to the
capability approach and its application in the mental
health context is available elsewhere [26, 27].
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Initial testing of OxCAP-MH 16-item index indicates
both the feasibility and face validity of directly measur-
ing capabilities in patients with severe mental illness
[26]. However, further work is required to establish the
instruments’ broader psychometric properties including
internal consistency, test-retest reliability and convergent
and discriminant validity and sensitivity to change.
Construct validity
The construct validity of the OxCAP-MH was evaluated
by comparing total scores of the OxCAP-MH to those
of previously validated measures of health-related quality
of life (EQ-5D), overall functioning (GAF), psychiatric
symptoms (BPRS), and objective social outcomes (SIX).
Convergent validity was assessed by examining the asso-
ciation between the OxCAP-MH and the EQ-5D, while
discriminant validity was determined by the associations
between the OxCAP-MH, GAF, BPRS and SIX.
The EQ-5D was used to assess convergent validity
because, among the instruments used in this study, it
was believed on theoretical grounds, to be the most
closely related to the OxCAP-MH. It was hypothesised
that the OxCAP-MH would correlate strongly with the
EQ-5D since the latter captures health-related quality of
life (which should overlap with the OxCAP-MH’s con-
cept of wellbeing), and both are multi-dimensional,
subjective, patient-reported outcome measures. In con-
trast, it was hypothesised that the association between
the OxCAP-MH and the GAF and BPRS would be mod-
est on the grounds that these instruments represent the
clinician/researcher’s impression of the patient’s overall
functioning and symptom severity respectively, while the
association with the SIX would be quite weak, since this
instrument captures only “objective facts” about the pa-
tient’s social situation, such as whether they have em-
ployment and housing. It was expected that OxCAP-
MH would be positively correlated with the GAF and
SIX and negatively correlated with the BPRS, since
higher BPRS scores indicate greater symptom severity.
These latter three measures are widely used within
psychiatry whereas the EQ-5D is more commonly used
in economics. Compared with all these, our measure ex-
plicitly monitors a wide set of aspects of quality of life.
Sensitivity to change
Sensitivity to change refers to the ability of the instrument
to measure any degree of change, while responsiveness re-
flects the ability to detect change over time that is clinic-
ally meaningful [28]. Sensitivity and responsiveness are
usually determined by evaluating the relationship between
changes in clinical and patient-rated endpoints and
changes in the instrument over time, usually within in a
clinical trial or observational study [29, 30].
So-called ‘distributional’ approaches are widely used to
evaluate sensitivity to change and are based on the stat-
istical features of the data produced by the instrument
[31]. The simplest approach to assess change in health
status is to calculate an ‘effect size’ which relates data on
change produced by the instrument to variance, usually
in the baseline data of the instrument [32]. A potentially
superior approach, however, is to calculate the standard
error of measurement (SEM) [33–35], which reflects the
instrument’s reliability as well as its variance [36]. The
SEM estimates the extent to which the observed change
is a true change rather than measurement error; thus,
any change score above the SEM can be considered sta-
tistically significant change in the sense that it is unlikely
to have arisen by chance.
One limitation of SEM, however, is that it is based on
information about scores at a single time point only ra-
ther than multiple time points. A more accurate meas-
ure of change would therefore require the calculation of
the difference (Sdiff ) between the SEM at two time
points in a longitudinal study [33, 37]. We employed
both approaches to assess sensitivity to change of the
OxCAP-MH in this study.
Aims
The aim of this study was to establish the psychometric
properties of the OxCAP-MH in terms of internal
consistency, test-retest reliability, convergent and dis-
criminant validity and sensitivity to change in a clinical
sample with psychotic illnesses.
Methods
Participants and setting
Data were collected at baseline as part of the Oxford
Community Treatment Order Evaluation Trial (OCTET,
trial registration number: ISRCTN73110773) between
2008 and 2012 [38]. Inclusion criteria were: aged
18-65 years, primary diagnosis of psychotic illness, cur-
rently detained for inpatient treatment, considered
suitable for a Community Treatment Order (CTO, a
legal regime mandating patients to adhere to treatment
while living in the community), and able to give
informed consent. Following recruitment, patients were
randomised to leave hospital either on a CTO or to vol-
untary treatment and followed up for 12 months. The
study was granted ethical approval by the Staffordshire
NHS Research Ethics Committee [REC ref. 08/H1204/
131] and all patients gave informed consent prior to
interview.
Study design
The reliability and validity analyses employed a cross-
sectional design. The sensitivity to change analysis used
a longitudinal design. All patients were interviewed at
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baseline and 12 months by trained researchers who
administered the instruments below. Socio-demographic
and clinical details were collected from medical records.
Patients were identified via participating clinicians. Inter-
views for the OCTET study lasted approximately one
hour (the OxCAP-MH took around five minutes to
complete) and patients were reimbursed with £25 for
each interview.
Test-retest data were collected as part of a follow-up
of the OCTET study 48 months after randomisation. All
participating patients were contacted twice with the
same postal questionnaire with a seven-day interval be-
tween questionnaires [39]. To eliminate bias due to
changes in patients’ mental state or social situation,
patients were asked the following question in the second
questionnaire: Since you last completed this question-
naire, has anything in relation to your mental health or
social situation changed? Patients who answered ‘yes’ to
this question were excluded from the test-retest analysis.
Instruments
Capabilities
The OxCAP-MH is a patient reported outcome measure
developed for use in mental health research. It was de-
veloped in several stages (see Simon et al. [26]). Initial
testing of a longer (18-item) version led to the removal
of two items (home ownership and life expectancy) fol-
lowing factor analysis. In a second version, two items
(Does your health affect your daily activities compared to
most people your age? and Are you able to meet socially
with friends and relatives?) were dichotomously coded
(yes/no) and then converted into a 1 to 5 scale (1 = 1
and 2 = 5) for scoring purposes, while all other items
were scored on a 1 to 5 Likert scale (e.g. strongly agree,
agree, neither agree nor disagree, disagree, strongly dis-
agree). In the final application of the instrument, includ-
ing the test-retest reliability, all 16 items were scored on
1 to 5 Likert scales.
The OxCAP-MH is scored on a 0–100 scale with
higher scores indicating better capabilities. Scores are
converted using the formula: 100 × (OxCAP-MH total
score – minimum score)/range. Items 2, 4, 5, 6, 9, 10,
11, 12, 13, 14, 15 and 16 are reversed coded. A full
version of the questionnaire can be found online at
http://healtheconomics.meduniwien.ac.at/science-researc
h/oxcap-mh/.
Health-related quality of life
The EQ-5D [11, 40] is a self-complete questionnaire that
assesses health-related quality of life at the time of inter-
view, and has two components. The EQ-5D-3L is a five-
item questionnaire with three levels for each question,
ranging from not present (1) to severe disability (3).
Scores for the 3L are then converted to standardised
‘utilities’ based on UK population norms, ranging from
−0.59 to 1, with 1 being the equivalent of perfect health
and zero the equivalent of dead. The EQ-5D Visual
Analogue Scale (VAS) is a 0 to 100 measure of current
health status where 0 and 100 represent the worst and
best imaginable health states respectively. The EQ-5D is
a generic, multi-attribute instrument widely used in
health economics research as the main outcome meas-
ure for cost-utility analyses. Reference to the EQ-5D in
this study is to the 3 Level (3L) version throughout.
Psychopathology
The Brief Psychiatric Rating Scale (BPRS) [41, 42] is a
clinician rated measure of psychiatric symptom severity
based on the two weeks prior to interview. The instru-
ment has 24 items that are rated on a seven point scale
from not present (1) to extremely severe (7). It has a
minimum score of 24 and maximum of 168, with higher
scores indicating poorer functioning.
Overall functioning
The Global Assessment of Functioning (GAF) [43] is a
clinician rated measure of overall functioning. It com-
bines symptoms and social/occupational functioning
into a single score from 0 to 100 with higher scores indi-
cating superior functioning.
Objective social outcomes
The Objective Social Outcomes Index (SIX) [44] is a brief
index used for benchmarking social outcomes by captur-
ing objective information about an individual’s social
situation in three domains: employment, living situation
and social contacts. The instrument scores from 0 to 6
with higher scores indicating better outcomes.
Statistical analyses
Data were checked for normality using the one-sample
Kolmogorov-Smirnov test of goodness of fit. Descriptive
statistics of socio-demographic and clinical characteris-
tics used means (SD) for normally distributed data, me-
dians (IQR) for non-normally distributed data, and
number (%) for categorical data. Between-group compar-
isons used t-tests for normally distributed data, Mann-
Whitney U tests for non-normal data, and Chi-square
tests for categorical data.
Floor and ceiling effects on individual items in the
index were calculated for all Likert scale items and con-
sidered present if more than 40% of patients scored the
lowest or highest score respectively [28]; for total
OxCAP-MH scores, effects were considered present if
more than 15% of respondents scored the lowest or
highest possible score respectively [45].
The reliability of the OxCAP-MH was evaluated in the
following ways. The internal consistency was assessed
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using Cronbach’s alpha where values of 0.70 and over
were considered satisfactory. Corrected item-total corre-
lations were calculated to assess redundancy of individ-
ual items, with scores from 0.2 to 0.8 considered
acceptable [28]. The test-retest reliability was established
by calculating the intraclass correlation coefficient using
a two-way random model with absolute agreement.
Convergent validity was assessed by calculating the
Pearson correlation coefficients for the OxCAP-MH and
the EQ-5D using UK tariff and VAS scores, while
discriminant validity was determined by calculating the
Pearson correlation coefficients for the OxCAP-MH and
the BPRS, GAF and SIX with lower correlation values
expected.
Sensitivity to change was assessed as follows. Baseline
mean (SD), 12-month follow-up mean (SD) and internal
consistency reliability coefficients were calculated for the
OxCAP-MH (16-items). The baseline and follow-up
SEM was calculated using the following formula:
SEM ¼ σx
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−rxx
p
Where σ is the standard deviation of the score and r is
the reliability of the instrument. SEM scores were calcu-
lated from the baseline and 12-month follow-up
OxCAP-MH scores. SEMs were then used to obtain the
Sdiff using the following formula:
Sdiff ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SEM21 þ SEM22
 
q
There is currently no consensus about how many
SEMs a score must change for it to be considered a clin-
ically meaningful change for the individual. It has been
argued that a difference of one-SEM frequently corre-
sponds to a minimally important difference [35], al-
though a more conservative approach can be used which
multiplies the SEM by 1.96 and corresponds with the
95% confidence interval [46, 47]. Using higher SEM
multiplier simply means that higher change scores are
required to identify change scores that are unlikely to
have arisen by chance. We report both.
All data were analysed using SPSS version 20 [48].
Results
Participant characteristics
A total of 336 patients were randomised in the OCTET
Trial. Of these, one patients withdrew and two were in-
eligible [38]. Complete OxCAP-MH and other relevant
outcome baseline data were available for 172 patients.
Statistical analyses for the OxCAP-MH validation study
were carried out on this sample. The characteristics of
patients in this subsample did not differ significantly
from the full cohort, other than there being more
patients living homeless in the full cohort 35 (11%),
compared to 3 (2%) in the sub-sample (Table 1).
Of the 172 patients included in the analysis, 124 (72%)
were male; 101 (59%) were white, 43 (25%) were black, 16
(9%) were Asian and 12 (7%) were of ‘other’ ethnic origin;
153 (89%) had a primary diagnosis of schizophrenia,
schizotypal or delusional disorder, while 19 (11%) had a
diagnosis of other psychotic disorders (including bipolar
disorder). Patients had a mean age of 38 years (SD = 11)
and a mean illness duration of 13 years (SD = 10). At
baseline, 147 (85%) of patients were receiving incapacity
benefit; 142 (83%) had independent accommodation; 2
(2%) were in regular paid employment; and 19 (11%) were
married or lived with a partner. Details of the socio-demo-
graphic and clinical characteristics of the participants are
presented in Table 1.
Floor and ceiling effects
A ceiling effect was identified in two items with 42% of
respondents reporting having ‘very suitable’ accommoda-
tion and 43% reporting feeling ‘very safe’ walking alone
near their home; a floor effect was observed in one item
with 43% of respondents reporting ‘never’ losing sleep
over worry in the past four weeks. Overall, however,
there was no evidence of floor or ceiling effects in the
total OxCAP-MH scores, with less than 15% of respon-
dents scoring either the highest or lowest scores [45].
(Additional file 1).
Reliability of the OxCAP-MH
The OxCAP-MH was found to have substantial internal
consistency with Cronbach’s alpha of 0.79. Corrected
item-total correlations were considered satisfactory and
ranged from 0.20 to 0.59 [28]. Of the 311 test-retest reli-
ability questionnaires sent out, 57 were completed at
both time points and returned. Patients who returned
the questionnaire were more likely to have independent
accommodation compared to the overall sample con-
tacted (86% vs. 71%, p < .05), but otherwise did not sig-
nificantly differ in their baseline socio-demographic
characteristics. Five patients who reported a change in
their mental health or social situation were excluded
from analysis. Two questionnaires were excluded due to
missing data. A sample of 50 was retained for analysis.
The test-retest reliability analysis generated a sin-
gle-measure intraclass correlation coefficient of 0.86
(p < .001) (Fig. 1). Linear regression produced a stan-
dardised coefficient of 0.86 (P < .001) and adjusted R2
of 0.73, supporting the substantial reliability observed.
Validity of the OxCAP-MH
Pearson correlations between OxCAP-MH total scores
and the other instruments are presented in Table 2.
Correlations were highest with the EQ-5D VAS (.522,
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p < .001, n = 171) and EQ-5D-3L Utilities (.452, p < .001,
n = 170) followed by the BPRS (−.413, p < .001, n = 172).
The negative association with the BPRS was expected as
higher scores on this instrument indicate poorer function-
ing. A weaker association was observed between OxCAP-
MH total scores and the GAF (.240, p < .001, n = 171) and
SIX (.118, p = ns, n = 172). Correlations between the indi-
vidual items of the OxCAP-MH and established measures
of symptom severity, functioning, and outcome can be
seen in Additional file 2.
Sensitivity to change
Complete data for the OxCAP-MH were available for
104 patients at both baseline and 12-months follow-up.
The SEM values for baseline and follow-up and values
for Sdiff using the two criteria (one-SEM and 1.96*SEM)
are presented in Table 3. Between baseline and follow-
up there was a small increase in mean capability scores
from 68 to 71.
Using the one-SEM of change criterion, a score of 6.47
on a 0–100 scale can be considered a statistically im-
portant difference. This cut off increases to 12.68 when
the more conservative 1.96 * SEM criterion is applied.
The standard error of the difference (Sdiff ) shows that a
minimally significant change from baseline to 12-months
follow-up corresponds to a 9.16 points of change on a
Table 1 Socio-demographic and clinical characteristics of psychosis
patients included in the OCTET RCT and patients with complete
OxCAP-MH data (N= 172)
OCTET RCT
missing data
(N = 333)
OCTET RCT
(N = 333)
OxCAP-MH validation
study
(N = 172)
Age 0 (0%) 39.6 (11.4) 38.2 (11.2)
Sex 0 (0%)
Male 224
(67.3%)
127 (72%)
Female 109 (33%) 48 (28%)
Years of education 4 (1.2%) 11.9 (1.9) 11.9 (1.9)
Ethnic origin 0 (0%)
White British 204 (61%) 101 (59%)
Black 77 (27%) 43 (25%)
Asian 29 (9%) 16 (9%)
Mixed and other 23 (7%) 12 (7%)
Born in the UK 1 (<1%) 256 (77%) 137 (80%)
Marital status 2 (<1%)
Single 247 (74%) 128 (74%)
Married/co-habiting 29 (9%) 19 (11%)
Separated/divorced 55 (17%) 25 (15%)
Have children 2 (<1%) 134 (40%) 67 (39%)
Living situation 2 (<1%)
Independent
accommodation
238 (72%) 142 (83%)
Supported
accommodation
58 (17%) 27 (16%)
Homeless 35 (11%)* 3 (2%)*
Employment 1 (<1%)
Incapacity benefit 292 (88%) 147 (85%)
Regular paid 2 (<1%) 2 (2%)
Voluntary/protected/
sheltered
2 (<1%) 2 (2%)
Job seeker’s
allowance
14 (4%) 9 (5%)
Unemployed,
no benefits
13 (4%) 7 (4%)
Other (student/
pensioner)
9 (3%) 5 (3%)
Clinical diagnosis 0 (0%)
Schizophrenia 283 (85%) 153 (89%)
Other psychoses 50 (15%) 19 (11%)
BPRS 22 (7%) 38.7 (11.4) 37.3 (10.4)
GAF 24 (7%) 38.7 (9.7) 40.5 (9.6)
Duration of illness
(years)
8 (2%) 14.3 (10.3) 13.2 (10.1)
No. of past psychiatric
hospital admissions
21 (6%) 5 [3–9] 5 [3–8]
Data are number (%), mean (SD), or median [IQR]. BPRS Brief Psychiatric
Rating Scale, GAF Global Assessment of Functioning
Percentages may not sum to 100 due to rounding
*Significant at the .05 level
Fig. 1 OxCAP-MH test-retest reliability based on total scores collected
one week apart (n = 50)
Table 2 Pearson correlations between the OxCAP-MH total scores
and established measures of illness severity, functioning and social
outcomes
OxCAP-MH EQ-5D 3L EQ-5D VAS BPRS GAF
EQ-5D-3L Utility .452**
EQ-5D VAS .522** .517**
BPRS −.413** −.411** −.325**
GAF .240** .233** .203** −.443**
SIX .118 .129 .100 −.056 .159*
EQ-5D 3L EuroQol-3L Utility, EQ-5D VAS EuroQol Visual Analogue Scale, BPRS
Brief Psychiatric Rating Scale, GAF Global Assessment of Functioning, SIX
Objective Social Outcomes Index
** Significant at the .001 level * Significant at the .05 level
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0–100 scale; this threshold increases to 17.96 when the
1.96*SEM criterion is used.
Using the one-SEM Sdiff criterion of statistically signifi-
cant change between baseline and follow-up (9.16), 24
(23%) patients improved, 67 (64%) showed no change,
and 13 (12%) deteriorated. For these three groups, the
mean (SD) capabilities scores at 12-months follow-up
were 74.5 (11.5), 70.0 (12.3) and 68.4 (8.8). Using the
more stringent 1.96*SEM Sdiff threshold of 17.96, 8 (8%)
patients improved, 92 (88%) showed no change, and 4
(4%) deteriorated. These three groups had mean (SD)
capabilities scores at 12-months follow-up of 74.8 (12.2),
70.7 (12.0) and 65.2 (5.6) respectively.
Distribution of the OxCAP-MH scores
The distribution of total scores for the OxCAP-MH,
EQ-5D-3L Utilities, EQ-5D VAS, BPRS and GAF are
presented in Fig. 2 (Frequency = number of cases). Panel
A shows that patients’ total scores for the OxCAP-MH
are normally distributed.
Discussion
This study reports the statistical evaluation of the psy-
chometric properties of a multi-dimensional capability
instrument designed for use in a mental health context.
The instrument showed strong psychometric properties.
Reliability and validity
The OxCAP-MH was found to have good reliability: the
internal consistency was evidenced by a Cronbach’s
alpha of 0.79 whilst the test-retest reliability measured
by an intraclass correlation coefficient of 0.86 – both
substantial correlations significant at the p < 0.001 level.
Results also support the validity of the OxCAP-MH. The
convergent validity of the instrument was demonstrated
by its strong correlation with established measures of
health-related quality of life (EQ-5D) and illness severity
(BPRS). The modest correlation with overall functioning
(GAF) and an objective measure of social outcomes
(SIX) supports the divergent validity of the instrument.
The strength of these associations can be partially
accounted for by the theoretical relationship between
the instruments.
The EQ-5D is a widely used generic measure of
health-related quality of life. It has undergone extensive
reliability and validity testing with a range of health con-
ditions [49–54] and has arguably the closest theoretical
association with the OxCAP-MH. The EQ-5D and
OxCAP-MH both capture patients’ subjective appraisal
of their own quality of life evidenced by the strong and
statistically significant correlation between the instru-
ments. A perfect correlation between the instruments
would not be expected, however, since the OxCAP-MH
is designed to capture a much wider range of outcomes
than the EQ-5D including health and non-health
domains. The OxCAP-MH should capture health-
related quality of life and well-being but, as a multi-
dimensional measure, it should also capture more. Inter-
estingly, the OxCAP-MH correlated more strongly with
the EQ-5D VAS scores than with the Utility scores. One
possible explanation for this is that the Utility scores
capture specific aspects of quality of life – namely those
that are health-related – while the VAS reflects the pa-
tient’s judgement about their overall health status, which
is arguably more in line with the aims of the OxCAP-
MH which attempts to capture the patient’s overall
well-being [26]. Furthermore, because the dimensions of
life quality measured in the OxCAP-MH are conceptu-
ally diverse, the moderately high Cronbach alpha sug-
gests that the severe mental illnesses examined have
significant impact on most aspects of quality of life.
In contrast to the EQ-5D, correlations with the GAF –
a well-established clinician-rated measure of overall
(clinical and social) functioning – was 0.24, while the as-
sociation with the SIX – an objective index of social out-
comes – was just 0.12. Again, these associations can be
explained by the more distal theoretical relationship
between the GAF and SIX and the OxCAP-MH. The
GAF score represents a patient’s overall functioning as
perceived by the clinician/researcher, while the SIX
merely captures objective ‘facts’ about their social situ-
ation (like having employment) – neither would be ex-
pected to correlate highly with a patient’s subjective
appraisal of what they feel free to be and do i.e. their
capabilities. The validity of the OxCAP-MH is further
supported by its significant negative association with the
BPRS. This indicates that there is a strong negative
relationship between patients’ capabilities and
Table 3 SEM values for the OxCAP-MH at baseline and 12-months follow-up
Baseline (T1) Follow-up (T2) SEM Values
N = 104 N = 104 1 * SEM 1.96 * SEM
Mean (SD) Alphaa Mean (SD) Alphaa T1 T2 Diff.2 T1 T2 Diff.b
OxCAP-MH 67.67 (13.80) 0.78 70.81 (11.85) 0.70 6.47 6.49 9.16 12.68 12.72 17.96
SEM Standard error of measurement
aCronbach’s alpha coefficient
bSdiff ¼ √ SEM21 þ SEM22
 
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psychopathological symptoms. Associations between
all instruments used in this study and the 16 individ-
ual items of the OxCAP-MH are presented in
Additional file 2.
Ceiling effects were observed in two items in the
OxCAP-MH with 42% of respondents reporting having
‘very suitable’ accommodation and 43% reporting feeling
‘very safe’ walking alone near their home. These response
rates may reflect the particular wording of the questions
and the fact that the respondents live in a wealthy indus-
trialised country in which the majority of people do have
suitable accommodation and are subject to relative low
levels of crime. A floor effect was observed in one item
with 43% of respondents reporting ‘never’ losing sleep
over worry in the past four weeks. Although a small num-
ber of items demonstrated floor and ceiling effects they
were retained in the measure as they were regarded as im-
portant and contributed to the content validity of the
a b
c
e
d
Fig. 2 Distribution of patients’ total scores for instruments used in psychometric validation (panels a – e). Frequency = number of cases
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instrument. Furthermore, overall domain scores did not
indicate any such floor/ceiling effects.
Sensitivity to change
The results show that on average there was little change
in mean capabilities scores between baseline and
12-months follow-up, a finding that is consistent with
results from the OCTET Trial including secondary and
follow-up analyses [38, 55, 56]. The results show that
using the one-SEM criterion, a change of around 9.2 on
the OxCAP-MH 0–100 scale is unlikely to be due to
measurement error and can be considered on distribu-
tional grounds to be a true change in score. When the
more conservative 1.96 * SEM criterion is applied, this
threshold for true change increases to 18.0 points of
change. It is important to remember that these changes
are not necessarily clinically meaningful but rather rep-
resent differences that, on statistical grounds, are
unlikely to have arisen by chance.
The inclusion of approximate 95% confidence intervals
(1.96 * SEM or 1.96 * Sdiff ) substantially increased the
minimum significant – or ‘real’ – change score required
for the OxCAP-MH. Fitzpatrick and colleagues [33] note
that ‘for group-based evaluative research there is a risk
that calculating minimum change scores by distribu-
tional methods adjusted for 95% confidence intervals
will result in too conservative an approach with respon-
dents who experience important deterioration being
missed and treated as unchanged’ (p.1413). The use of
one-SEM or one-Sdiff would be in keeping with methods
used in several studies assessing change across a range
of health-related quality of life instruments in patients
with asthma, cardiac problems, Parkinson’s disease,
amyotrophic lateral sclerosis, and chronic obstructive
pulmonary disease [33–36, 57]. In these studies, one-
SEM was considered the optimal statistical criterion
consistent with anchor-based evidence [36]. Using the
one-SEM Sdiff criterion, an individual change score be-
tween baseline and 12-months follow-up that is greater
than 9 points would be considered an improvement or
deterioration in capabilities scores that did not arise due
to chance or measurement error.
The question of whether to use one-SEM (or one-Sdiff )
or to use confidence intervals and therefore more strin-
gent criteria for minimal change partly depends on
whether decisions are made with respect to groups or
individuals – for example, interpretation of clinical trials,
or an individual patient in a clinical context [36]. In gen-
eral, the group context is associated with greater confi-
dence in any given estimate of health related quality of
life while a clinician making health-related quality of life
decisions at the individual level may opt for the more
conservative approach gained from the confidence inter-
val adjusted scores to determine change [33, 36].
Distributions of OxCAP-MH scores
Figure 2 shows that compared with other indicators of
functioning and outcome used in this study, the
OxCAP-MH total scores follow a more normal distribu-
tion. This is important because an instrument that is
normally distributed is less likely to lose information to
floor or ceiling effects, which can compromise validity.
For example, a well-known limitation of the EQ-5D is its
propensity for ceiling effects, a finding that has been
shown repeatedly in range of patients groups [9] and the
general population [58]. Problems of sub-optimal score
distribution have also been observed for the GAF. Reli-
ability studies show that GAF scores can have restricted
distributions and can be unreliable; in one study 20% of
raters accounted for more than 50% of the spread of
scores, and deviations can be 20 points or more [59–61].
Figure 2 shows that the distribution of OxCAP-MH total
scores are not affected by floor or ceiling effects.
Strengths and limitations
The majority of concepts used to assess quality of life
have been introduced into healthcare not on the basis of
a theoretical model but rather on the basis of conveni-
ence or intuitive appeal [62]. A major strength of the
capability approach is therefore its theoretical pedigree.
Sen’s work proposes a model of human welfare that is
based on substantive freedoms to achieve the things that
an individual has reason to value rather than on relying
on resource and desire fulfilment typical of many trad-
itional quality of life frameworks [22]. Moreover, the
OxCAP-MH focuses on factors that link directly to peo-
ples’ broader well-being rather than relying on proxies
(such as health-related quality of life) as is the case with
the EQ-5D.
Measuring capabilities remains a challenge, however,
and there is ongoing theoretical discussion about which
capability domains are most important and how they
ought to be measured [18, 63]. The capability approach
is not directly linked with traditional conceptual frame-
works of health and quality of life, and there are com-
paratively few capability measures with which to
compare new instruments. The development and valid-
ation of a novel capability measure represents an
important conceptual and methodological development
within the capabilities literature as well as research on
health measurement.
The data used in this study could not fully address the
question of sensitivity to change of the OxCAP-MH. In
particular, the absence of a patient-rated anchor question
at 12-months follow-up means that the clinical meaning-
fulness of the instrument could not be tested. Among
the existing capability measures developed for use in
health contexts, evidence supporting their sensitivity to
change is limited and somewhat mixed [64–66]. Coast
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and colleagues [18] note that generic capability measures
cover a very broad informational space – i.e. the entirety
of the individual’s life rather than just their health for ex-
ample – which may make it more difficult to demon-
strate their sensitivity to change. These challenges
notwithstanding, demonstrating the sensitivity to change
of the OxCAP-MH remains essential if the instrument is
to be useful for distinguishing different interventions
and should be tackled in future studies.
Patients in this sample were mostly out-patients with
severe mental illnesses and further work is needed to
establish the feasibility and validity of using the instru-
ment in other settings (e.g. in-patient care) and with
other patient groups. Finally, it is also worth noting that
male participants were slightly over represented in this
sample and equal representation should be considered
in future studies.
Conclusions
The statistical validation described above shows that the
OxCAP-MH, the first mental health specific capabilities
instrument has good psychometric properties in terms
of reliability and validity. Some questions about the in-
strument’s sensitivity to change remain, however, and
further work with larger samples that include explicit
anchor-based questions is necessary. The results support
the use of self-reported capabilities to assess outcomes
in patients with severe mental illness for clinical, health
services and economic evaluations. The OxCAP-MH is
now freely available for non-profit purposes at: https://
healtheconomics.meduniwien.ac.at/science-research/oxcap
-mh/.
Additional files
Additional file 1: Floor and ceiling effects for OxCAP-MH items scored
on a 1 to 5 Likert scale. (DOCX 13 kb)
Additional file 2: Correlation of individual items of the OxCAP-MH with
established measures of illness severity, functioning and social outcomes.
(DOCX 13 kb)
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